dc.contributor.author | Gusman, Mariya | en_US |
dc.contributor.author | Fallows, Zak | en_US |
dc.coverage.temporal | Spring 2009 | en_US |
dc.date.issued | 2009-06 | |
dc.identifier | SP.236-Spring2009 | |
dc.identifier | local: SP.236 | |
dc.identifier | local: ES.SP236 | |
dc.identifier | local: IMSCP-MD5-6fe4ef5fb3fd0c58784ebb6164ea546a | |
dc.identifier.uri | http://hdl.handle.net/1721.1/85859 | |
dc.description.abstract | From Abilify to Zyrtec, the world is full of interesting drugs. Such substances have cured diseases, started wars, and ended careers. This seminar will explain how drugs can elicit a range of medicinal and recreational effects. Planned topics include over-the-counter drugs and "dietary supplements," drugs of abuse, treatments for neurological disorders, psychiatric medications, and many more. Prior experience is neither expected nor required, but student participation is essential. | en_US |
dc.language | en-US | en_US |
dc.rights.uri | Usage Restrictions: This site (c) Massachusetts Institute of Technology 2014. Content within individual courses is (c) by the individual authors unless otherwise noted. The Massachusetts Institute of Technology is providing this Work (as defined below) under the terms of this Creative Commons public license ("CCPL" or "license") unless otherwise noted. The Work is protected by copyright and/or other applicable law. Any use of the work other than as authorized under this license is prohibited. By exercising any of the rights to the Work provided here, You (as defined below) accept and agree to be bound by the terms of this license. The Licensor, the Massachusetts Institute of Technology, grants You the rights contained here in consideration of Your acceptance of such terms and conditions. | en_US |
dc.rights.uri | Usage Restrictions: Attribution-NonCommercial-ShareAlike 3.0 Unported | en_US |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/3.0/ | en_US |
dc.subject | pharmacology | en_US |
dc.subject | central nervous system | en_US |
dc.subject | neurotransmitters | en_US |
dc.subject | dopamine | en_US |
dc.subject | Parkinson's | en_US |
dc.subject | ADHD | en_US |
dc.subject | schizophrenia | en_US |
dc.subject | serotonin | en_US |
dc.subject | alcohol | en_US |
dc.subject | barbituates | en_US |
dc.subject | LSD | en_US |
dc.subject | acetylcholine | en_US |
dc.subject | endocannabinoids | en_US |
dc.subject | endocrine systems | en_US |
dc.subject | norepinephrine | en_US |
dc.subject | opioids | en_US |
dc.title | SP.236 / ES.SP236 Exploring Pharmacology, Spring 2009 | en_US |
dc.title.alternative | Exploring Pharmacology | en_US |
dc.type | Learning Object | |
dc.type | Learning Object | |
dc.type | Learning Object | |
dc.contributor.department | MIT Experimental Study Group | |
dc.contributor.department | MIT Experimental Study Group | |
dc.contributor.department | MIT Experimental Study Group | |